Skip to content
Inciteful Med

Life After Diagnosis: Long-Term Monitoring and Medication Withdrawal

Last updated:

Patients with a prolactinoma may eventually be able to stop taking medication like cabergoline after two years of normal hormone levels and significant tumor shrinkage. Long-term care involves monitoring prolactin levels, heart valve health, and bone density.

Key Takeaways

  • • Medication for a prolactinoma can often be safely tapered off after two years of normal prolactin levels and at least 50% tumor shrinkage.
  • • Long-term remission without medication is more common for microprolactinomas (65%) than for macroprolactinomas (36%).
  • • Patients taking cabergoline may require periodic echocardiograms to monitor for a very low risk of heart valve thickening.
  • • High prolactin levels can cause bone thinning, making regular bone density testing important, particularly for male patients.
  • • Large prolactinomas can crowd out healthy pituitary tissue, so doctors must regularly monitor thyroid and adrenal functions.

For many patients, a prolactinoma is a long-term companion rather than a short-term illness. While the initial goal is to normalize your hormones, the long-term focus shifts to maintaining that balance, monitoring for side effects, and—for some—eventually trying to live without medication [1][2].

Can I Ever Stop My Medication?

One of the most common questions patients ask is whether they must take medication forever. In many cases, it is possible to “withdraw” or taper off dopamine agonists like cabergoline, but this must be done carefully under medical supervision [3][4].

  • The 2-Year Rule: Doctors generally only consider withdrawing medication after you have had at least two years of normal prolactin levels on a stable dose [5][6].
  • Tumor Shrinkage: Most guidelines require that the tumor has shrunk significantly—usually by 50% or more—or has disappeared entirely from your MRI before trying to stop the drug [3][4].
  • Success Rates: Remission (staying off medication without the tumor returning) is more common for microprolactinomas (about 65%) than for macroprolactinomas (about 36%) [3].
  • The Risk of Recurrence: If you stop medication, your doctor will monitor you closely, especially in the first year, as this is when the hormone levels are most likely to rise again [3].

Long-Term Monitoring: The “Checklist”

Even if your prolactin levels are stable, your care team will continue to monitor several key areas of your health to ensure no long-term issues develop [7][8].

1. Heart Valve Health

If you are taking cabergoline, there is a very small risk that long-term use can cause thickening of the heart valves (fibrosis) [9][10].

  • Context: It is important to know that this risk was primarily discovered in Parkinson’s disease patients who take doses vastly higher (often 10x to 20x higher) than the typical endocrinology dose [11].
  • Low Dose: At the low doses typically used for prolactinomas, this risk is considered very low [11][12].
  • Monitoring: If your dose is higher than 2 mg per week, your doctor may recommend an echocardiogram (an ultrasound of the heart) every year; for lower doses, a scan every five years is often sufficient [13][14].

2. Bone Density

Because high prolactin can “thin” the bones, long-term monitoring of your bone health is essential [15][16].

  • DEXA Scans: These specialized X-rays measure bone mineral density.
  • Higher Risk for Men: Interestingly, men with prolactinomas often have a higher risk of long-term bone loss (osteoporosis) than women, even after their hormone levels are controlled, and may need more frequent testing [15][17].

3. Pituitary Function

Large tumors can sometimes “crowd out” the healthy parts of the pituitary gland, leading to hypopituitarism—a deficiency in other vital hormones [18][19].

  • Hormones to Watch: Your doctor may periodically check your thyroid (TSH) and adrenal (cortisol) functions, especially if you had a macroadenoma at diagnosis [20][19].

Coping with “Scan Anxiety”

Living with a chronic condition and undergoing regular MRIs can take a psychological toll. It is normal to feel “scan anxiety” (anxiety before an imaging test) or stress about long-term medication side effects [21].

Open communication with your care team and potentially joining a support group can help you manage the emotional aspects of the journey. Remember that for the majority of patients, the long-term outlook is excellent, and most lead full, active lives [22][2].

Return to Home

Frequently Asked Questions

Can I ever stop taking medication for my prolactinoma?
Yes, many patients can safely taper off medications like cabergoline under medical supervision. Doctors typically consider this only after you have maintained normal prolactin levels for at least two years and your tumor has shrunk by 50% or more.
Does taking cabergoline damage your heart valves?
There is a very small risk of heart valve thickening associated with long-term cabergoline use. However, because the doses used for prolactinomas are very low, this risk is minimal. Your doctor may recommend periodic echocardiograms to monitor your heart.
Why do I need bone density scans for a prolactinoma?
High prolactin levels can thin your bones over time, increasing the risk of osteoporosis. Long-term monitoring with DEXA scans helps ensure your bones stay healthy, which is especially important for men with prolactinomas.
Will my prolactinoma come back if I stop taking my medication?
The chance of staying in remission after stopping medication depends on your tumor size. About 65% of people with smaller microprolactinomas remain in remission, compared to approximately 36% of those with larger macroprolactinomas.
Why does my doctor check my thyroid and adrenal levels?
Large tumors can compress the healthy parts of the pituitary gland, leading to a condition called hypopituitarism where you lack other vital hormones. Your doctor will check your thyroid and cortisol levels to ensure your pituitary is functioning properly.

Questions for Your Doctor

  • • I have been on a stable dose of medication for over 2 years and my prolactin is normal—do I meet the criteria (like 50% tumor shrinkage) to try tapering off?
  • • How often will my prolactin be checked after I stop the medication, especially during the first year when recurrence is most likely?
  • • Based on my current weekly dose of cabergoline, how often should I have an echocardiogram to monitor my heart valves?
  • • As a male patient, should I have regular DEXA scans even if my testosterone and prolactin levels are now normal?
  • • Since I have a large tumor, should we re-test my thyroid and adrenal (cortisol) levels to see if my pituitary function has recovered?

Questions for You

  • • Have you felt any new or returning symptoms, like headaches or changes in your vision, since your last scan?
  • • If you have recently stopped or lowered your medication, have you noticed any changes in your mood, energy, or menstrual cycle?
  • • How do you feel about the idea of stopping medication—are you more anxious about the side effects of the drug or the possibility of the tumor returning?
  • • Are you keeping a log of your medication doses and blood test results to track your progress over the years?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement.

    Petersenn S, Fleseriu M, Casanueva FF, et al.

    Nature reviews. Endocrinology 2023; (19(12)):722-740 doi:10.1038/s41574-023-00886-5.

    PMID: 37670148
  2. 2

    Treatment of hyperprolactinemia: A single-institute experience.

    Chen TY, Lee CH, Yang MY, et al.

    Journal of the Chinese Medical Association : JCMA 2021; (84(11)):1019-1022 doi:10.1097/JCMA.0000000000000584.

    PMID: 34261980
  3. 3

    Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?

    Dogansen SC, Selcukbiricik OS, Tanrikulu S, Yarman S

    Pituitary 2016; (19(3)):303-10 doi:10.1007/s11102-016-0708-3.

    PMID: 26830552
  4. 4

    The Role of Dopamine Agonists in Pituitary Adenomas.

    Giraldi EA, Ioachimescu AG

    Endocrinology and metabolism clinics of North America 2020; (49(3)):453-474 doi:10.1016/j.ecl.2020.05.006.

    PMID: 32741482
  5. 5

    Controversial issues in the management of hyperprolactinemia and prolactinomas - An overview by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism.

    Vilar L, Abucham J, Albuquerque JL, et al.

    Archives of endocrinology and metabolism 2018; (62(2)):236-263 doi:10.20945/2359-3997000000032.

    PMID: 29768629
  6. 6

    Recurrence of hyperprolactinemia following dopamine agonist withdrawal and possible predictive factors of recurrence in prolactinomas.

    Sala E, Bellaviti Buttoni P, Malchiodi E, et al.

    Journal of endocrinological investigation 2016; (39(12)):1377-1382 doi:10.1007/s40618-016-0483-z.

    PMID: 27245604
  7. 7

    Magnetic resonance imaging in the management of prolactinomas; a review of the evidence.

    Varlamov EV, Hinojosa-Amaya JM, Fleseriu M

    Pituitary 2020; (23(1)):16-26 doi:10.1007/s11102-019-01001-6.

    PMID: 31659622
  8. 8

    Lipid Profile Differences in Monomeric Hyperprolactinemia, Macroprolactinemia, and Healthy Controls: A Comparative Analysis.

    Bahçebaşı S, Gökay F, Şimşek Y

    Neuroendocrinology 2025; (115(9)):719-729 doi:10.1159/000547540.

    PMID: 40864600
  9. 9

    [Clinical practice considerations on cabergoline in the treatment of pituitary prolactinoma].

    Ye HY, Ji LJ

    Zhonghua yi xue za zhi 2025; (105(41)):3743-3746 doi:10.3760/cma.j.cn112137-20250810-02028.

    PMID: 41218890
  10. 10

    A Follow-Up Study of the Prevalence of Valvular Heart Abnormalities in Hyperprolactinemic Patients Treated With Cabergoline.

    Drake WM, Stiles CE, Bevan JS, et al.

    The Journal of clinical endocrinology and metabolism 2016; (101(11)):4189-4194 doi:10.1210/jc.2016-2224.

    PMID: 27571182
  11. 11

    The risks of medical treatment of prolactinoma.

    Castinetti F, Albarel F, Amodru V, et al.

    Annales d'endocrinologie 2021; (82(1)):15-19 doi:10.1016/j.ando.2020.12.008.

    PMID: 33373604
  12. 12

    Long-term cardiac (valvulopathy) safety of cabergoline in prolactinoma.

    Khare S, Lila AR, Patil R, et al.

    Indian journal of endocrinology and metabolism 2017; (21(1)):154-159 doi:10.4103/2230-8210.196010.

    PMID: 28217516
  13. 13

    Echocardiography and monitoring patients receiving dopamine agonist therapy for hyperprolactinaemia: a joint position statement of the British Society of Echocardiography, the British Heart Valve Society and the Society for Endocrinology.

    Steeds RP, Stiles CE, Sharma V, et al.

    Echo research and practice 2019; (6(1)):G1-G8.

    PMID: 30825409
  14. 14

    Echocardiography and monitoring patients receiving dopamine agonist therapy for hyperprolactinaemia: A joint position statement of the British Society of Echocardiography, the British Heart Valve Society and the Society for Endocrinology.

    Steeds R, Stiles C, Sharma V, et al.

    Clinical endocrinology 2019; (90(5)):662-669 doi:10.1111/cen.13940.

    PMID: 30818417
  15. 15

    Persistent bone impairment despite long-term control of hyperprolactinemia and hypogonadism in men and women with prolactinomas.

    Andereggen L, Frey J, Andres RH, et al.

    Scientific reports 2021; (11(1)):5122 doi:10.1038/s41598-021-84606-x.

    PMID: 33664388
  16. 16

    Hyperprolactinemia Due to Prolactinoma has an Adverse Impact on Bone Health with Predominant Impact on Trabecular Bone: A Systematic Review and Meta-Analysis.

    Nagendra L, Dutta D, Mondal S, et al.

    Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry 2024; (27(1)):101453 doi:10.1016/j.jocd.2023.101453.

    PMID: 38064881
  17. 17

    Impact of medical therapy for hormone-secreting Pituitary tumors on bone.

    Freda PU

    Pituitary 2024; (27(6)):860-873 doi:10.1007/s11102-024-01421-z.

    PMID: 38967763
  18. 18

    Recovery of hypopituitarism in macroprolactinomas: a comparison of medical vs. surgical treatment. Results from a European multicenter study.

    Detomas M, Altieri B, Nasi-Kordhishti I, et al.

    Journal of endocrinological investigation 2025; (48(6)):1363-1370 doi:10.1007/s40618-025-02559-8.

    PMID: 40035956
  19. 19

    Hypopituitarism patterns among adult males with prolactinomas.

    Peng J, Qiu M, Qi S, et al.

    Clinical neurology and neurosurgery 2016; (144()):112-8.

    PMID: 27038873
  20. 20

    Management of prolactinoma: a survey of endocrinologists in China.

    Ji L, Yi N, Zhang Q, et al.

    Endocrine connections 2018; (7(10)):1013-1019.

    PMID: 30352394
  21. 21

    Impulse Control Disorders in Patients With Hyperprolactinemia on Dopamine Agonist Therapy-How Concerned Should We Be?

    Daftari G, Tritos NA

    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2025; (31(7)):938-945 doi:10.1016/j.eprac.2025.04.018.

    PMID: 40316139
  22. 22

    Management outcomes of prolactinoma: a retrospective study from Southern Iraq.

    Alobaidy HF, Alidrisi HA, Reman KA, et al.

    Journal of medicine and life 2025; (18(9)):869-877 doi:10.25122/jml-2025-0050.

    PMID: 41178903

This page provides educational information about long-term prolactinoma care and medication withdrawal. Always consult your endocrinologist before making any changes to your treatment plan.

Stay up to date

Get notified when new research about Prolactinoma is published.

No spam. Unsubscribe anytime.